GlassScriptPhysician profile
Sheikh A Ali
NPI 1285830265
$342.49
in general payments reported to CMS, 2019-2025
11 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.02 · 2021: $11.40 · 2022: $20.99 · 2023: $26.63 · 2024: $132 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.59 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $112.95 | 2023-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $56.31 | 2020-2025 | Opdivo |
| Mallinckrodt Hospital Products INC. | $35.23 | 2024 | Acthar |
| Genentech USA, INC. | $20.99 | 2022 | |
| Pfizer INC. | $18.71 | 2024 | |
| Abbvie INC. | $18.41 | 2024 | |
| Adc Therapeutics America, INC. | $11.40 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheikh Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.